Jump to section
To create a global early warning system for infectious diseases.
-3% employee growth in 12 months
The global response to the COVID-19 outbreak prompted a collective realization among companies and governments about the enduring significance of infectious disease outbreaks as long-term risks requiring swift attention. This newfound awareness fueled a substantial increase in demand for BlueDot's SaaS platform, a specialized tool for outbreak intelligence. Leveraging refined machine-learning capabilities, BlueDot distinguishes itself by disseminating information about outbreaks more rapidly than almost any other global organization.
Initially catering predominantly to governmental bodies, BlueDot has witnessed a paradigm shift as private companies recognize the value of early warnings for infectious diseases. Seizing on this heightened interest, the company has redirected its focus toward establishing partnership programs and disseminating critical information through consultancies.
This strategic emphasis on fostering long-term partnerships positions BlueDot to counteract any potential decline in interest as concerns around coronaviruses and other infectious diseases gradually diminish in the coming years. By actively engaging in collaborative ventures, the company aims to maintain relevance and contribute to global health intelligence beyond the immediate impact of the pandemic.
Kirsty
Company Specialist at Welcome to the Jungle
Jan 2023
$3m
GRANT
Aug 2019
$6.9m
SERIES A
This company has top investors
Kamran Khan
(CEO)A practicing Infectious Disease Physician and an Associate Professor of Medicine with the Division of Infectious Diseases at the University of Toronto where they created an early warning system for infectious diseases that became BlueDot.